ArticleDiabetes & metabolism journal2023
Dyslipidemia Fact Sheet in South Korea, 2022.
Article in Diabetes & metabolism journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Sex-Specific Prevalence and Associated Factors of Dyslipidemia in Korean Adults: A Cross-Sectional Study.Health science reports · 2026Article
- Machine Learning Prediction Model for Dyslipidemia and Its Association With Atherothrombotic Events in 3 Independent Cohorts From South Korea, Japan, and the United Kingdom: Algorithm Development and Validation Study.JMIR medical informatics · 2026Article
- Association between sleep duration and dyslipidemia in premenopausal and postmenopausal women.BMC public health · 2026Article
- Genetic Influence ofInternational journal of molecular sciences · 2026Article
- Impaired insulin secretion via the Wnt5a/β-catenin pathway contributes to diabetes development in pancreatic cancer.Experimental & molecular medicine · 2026Article
- Nationwide Trends and Future Projections of Diabetes and Diabetic Retinopathy Prevalence in Korea: Korean National Health and Nutrition Examination Survey Study.Journal of Korean medical science · 2026Article
- Age at Menarche, Cardiometabolic Disease Prevalence, and Disease Control in Korean Women: Analysis of the Korea National Health and Nutrition Examination Survey.International journal of medical sciences · 2026Article
- Association between intake of different types of kimchi and dyslipidemia in Korean adults: a prospective cohort study.Frontiers in nutrition · 2026Article
- Association Between Lipid-Lowering Drug Use and Sarcopenia: Analysis of the Korea National Health and Nutrition Examination Survey.Journal of lipid and atherosclerosis · 2026Article
- Long-term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study.Frontiers in endocrinology · 2026Article
- High hepatic insulin resistance is linked to glucose and lipid profiles in Korean adults with type 2 diabetes.Frontiers in endocrinology · 2026Article
- Interactive effects of high-density lipoprotein cholesterol and insulin resistance on depression: results from the NHANES (2005-2018).Lipids in health and disease · 2025Article
- Causal effect of kimchi intake on HDL-cholesterol levels in middle aged Korean men: a two-sample Mendelian randomization analysis.Genes & nutrition · 2025Article
- Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022.Journal of obesity & metabolic syndrome · 2025Article
- Risk of Sarcopenic Obesity Across Menopausal Transition Stages in Middle-Aged Korean Women.Nutrients · 2025Article
- Comparative Effectiveness and Safety of Moderate-Intensity Pravastatin Versus Atorvastatin in Patients with Dyslipidemia: A Retrospective Cohort Study Using a Common Data Model of Multicenter Electronic Health Records in South Korea.Journal of atherosclerosis and thrombosis · 2025Article
- Sex- and age-specific determinants of diabetes: Insights from BKMR and cox modelling of metabolic and lifestyle risk factors in a Korean cohort.Diabetes, obesity & metabolism · 2025Article
- Pharmacologic Potential of Statins in Cancer Prevention: Colo-Rectal Cancer Risk in Dyslipidemic Patients from a Korean Nationwide Cohort.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A genome-wide study on gene-nutrient interactions for hyperuricemia in a large Korean cohort (KoGES).Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgruoundThis study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022.
methodsWe analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020.
resultsIn South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia-more than one out of three conditions (low-density lipoprotein cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein cholesterol [HDL-C] [men and women] <40 mg/dL)-was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-HDL-cholesterolemia in women changed from <40 to <50 mg/dL.
conclusionAlthough the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.